Genomic alterations of both TP53 (80.8% vs. 35.3%, p < 0.001) and ERBB2 (27.4% vs. 6.9%, p < 0.001) were more frequent in non-endometrioid carcinomas (Figure 3A). This evidence concerns the gene ERBB2 and endometrioid adenocarcinoma.